Abstract
The research of efficacious non-invasive therapies for the treatment of brain diseases represents a huge challenge, as people affected by disorders of the central nervous system (CNS) will significantly increase. Moreover, the blood-brain barrier is a key factor in hampering a number of effective drugs to reach the CNS. This review is therefore focusing on possible interventions of nanomedicine-based approaches in selected diseases affecting the CNS. A wide overview of the most outstanding results on preclinical evaluations of the potential of nanomedicine in brain diseases (i.e. brain tumor, Alzheimer, Parkinson, epilepsy and others) is given, with highlights on the data with relevant interest and real possibility in translation from bench-to-bedside. Moreover, a critical evaluation on the rationale in planning nanosystems to target specific brain pathologies is described, opening the path to a more structured and pathology-tailored design of nanocarriers.
Keywords: Blood-brain barrier, brain diseases, central nervous system, liposomes, nanomedicine, nanoparticles.
CNS & Neurological Disorders - Drug Targets
Title:Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain
Volume: 15 Issue: 9
Author(s): Barbara Ruozi, Daniela Belletti, Francesca Pederzoli, Flavio Forni, Maria Angela Vandelli and Giovanni Tosi
Affiliation:
Keywords: Blood-brain barrier, brain diseases, central nervous system, liposomes, nanomedicine, nanoparticles.
Abstract: The research of efficacious non-invasive therapies for the treatment of brain diseases represents a huge challenge, as people affected by disorders of the central nervous system (CNS) will significantly increase. Moreover, the blood-brain barrier is a key factor in hampering a number of effective drugs to reach the CNS. This review is therefore focusing on possible interventions of nanomedicine-based approaches in selected diseases affecting the CNS. A wide overview of the most outstanding results on preclinical evaluations of the potential of nanomedicine in brain diseases (i.e. brain tumor, Alzheimer, Parkinson, epilepsy and others) is given, with highlights on the data with relevant interest and real possibility in translation from bench-to-bedside. Moreover, a critical evaluation on the rationale in planning nanosystems to target specific brain pathologies is described, opening the path to a more structured and pathology-tailored design of nanocarriers.
Export Options
About this article
Cite this article as:
Ruozi Barbara, Belletti Daniela, Pederzoli Francesca, Forni Flavio, Vandelli Angela Maria and Tosi Giovanni, Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain, CNS & Neurological Disorders - Drug Targets 2016; 15 (9) . https://dx.doi.org/10.2174/1871527315666160915112210
DOI https://dx.doi.org/10.2174/1871527315666160915112210 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Opinion Paper: Post-surgical Delirium, Consciousness, and Therapy
Recent Patents on CNS Drug Discovery (Discontinued) Editorial [Hot Topic: Potassium Channels (Guest Editor: Dr. Vincenzo Calderone)]
Current Topics in Medicinal Chemistry The Role of IRE1 Signaling in the Central Nervous System Diseases
Current Neuropharmacology Antiepileptic Drugs for the Treatment of Impulsivity
Current Psychiatry Reviews FMRI of the Emotions: Towards an Improved Understanding of Amygdala Function
Current Medical Imaging Preface
Current Drug Targets - CNS & Neurological Disorders Kynurenines in the Central Nervous System: Recent Developments
Central Nervous System Agents in Medicinal Chemistry Potential Crossreactivity of Human Immune Responses Against HCMV Glycoprotein B
Current Drug Discovery Technologies Astrocytic Target Mechanisms in Epilepsy
Current Medicinal Chemistry The Current WHO Classification of Tumours of the Central Nervous System: Histopathology and Additional Diagnostic Methods
Current Medical Imaging Astrocyte-Neuron Interaction at Tripartite Synapses
Current Drug Targets Activation of Adenosine Receptor Potentiates the Anticonvulsant Effect of Phenytoin Against Amygdala Kindled Seizures
CNS & Neurological Disorders - Drug Targets Natural Polymeric Nanoparticles for Brain-Targeting: Implications on Drug and Gene Delivery
Current Pharmaceutical Design A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem
Current Pharmaceutical Biotechnology Deep Brain Stimulation for Alzheimer’s Disease
Current Alzheimer Research Mobilization and Redistribution of Default Mode Network from Resting State to Task State in Amnestic Mild Cognitive Impairment
Current Alzheimer Research Serum Insulin Degrading Enzyme Level and Other Factors in Type 2 Diabetic Patients with Mild Cognitive Impairment
Current Alzheimer Research Pharmacological Treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults
Current Psychiatry Reviews Neurological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry